7-Methoxy-4-trifluoromethylcoumarin (MFC) has been used extensively in high-throughput screens for the identification of potential CYP2C9 interactions. More recently, additional probes from Invitrogen have been used. Vivid 2C9 Green is the largest of the probes and has had limited prior characterization. The new series of probes differ significantly from MFC and were examined for their ability to identify interactions with 19 CYP2C9 substrates/inhibitors. The inhibition profiles depend largely on the physical differences between the fluorescent probe substrates. Cytochrome b5 (cyt b5) was also investigated for the ability to alter the inhibition profile of a given compound. The stoichiometric addition of cyt b5 caused an increase in Vmax of MFC and Vivid 2C9 Green 4.4 and 1.7 times, respectively. Furthermore, cyt b5 imposes a steric component to the active site as the inhibition profiles were significantly affected in incubations with MFC. The addition of cyt b5 had limited impact on the inhibition profiles generated with Vivid 2C9 Green. The K m of Vivid 2C9 Green increased from 1.2 ± 0.2 µM to 4.8 ± 0.3 µM as a result of cyt b5 addition. These results illustrate that multiple substrate probes may be necessary for screening drug-drug interaction in CYP2C9 and that cyt b5 effects can impart steric restraints on the CYP2C9 active site. (Journal of Biomolecular Screening 2006:303-309) Velocity (Fluor/min/pmol P450) B FIG. 3. (A) 7-methoxy-4-trifluoromethylcoumarin (MFC) inhibition profile of compounds with and without cyt b5. (B) Vivid 2C9 Green inhibition profile of compounds with and without cyt b5.
INTRODUCTION
C YTOCHROMES P450 display a broad overlap of substrates and are the source of most clinically observed drug-drug interactions. [1] [2] [3] To determine the potential for drug interactions of new compounds in preclinical testing, fluorescent probe substrates are often used as a high-throughput screening tool. 4, 5 Some fluorescent probes lack pharmacophore traits specific to each individual CYP, which may increase the possibility for false negatives in a screening. This may explain the low correlation of many fluorescent-based probes to clinical drug probes. 5 In addition, the lack of specificity requires the use of recombinant expressed CYP enzymes. Recombinant CYPs can be purchased with or without the cofactor cyt b5, which may introduce variability in the corresponding IC 50 s and inhibition profiles of a compound. Ultimately, the incubation conditions (presence or absence of cyt b5) could change the inhibition profile of a compound and possibly lead to spurious results. For this reason, increased characterization of fluorescent probe-CYP interactions is needed to identify the limitations of fluorescent probes and their ability to define drug-drug interactions of new chemical entities in CYP2C9.
7-Methoxy-4-trifluoromethylcoumarin (MFC) is a coumarinbased compound that undergoes O-demethylation by CYP2C9 to yield the fluorescent metabolite 7-hydroxy-4-trifluoromethylcoumarin (HFC). In addition to the inhibition of MFC, certain compounds screened against MFC have been shown to activate the metabolism of MFC. 6 The binding affinity of MFC for CYP2C9 likely results from the pi stacking interactions between the coumarin ring of MFC with 1 or more of the key phenylalanine residues (Phe 110, 114, or 476) within the CYP2C9 active site. In contrast, Vivid 2C9 Green is a large fluorescein-based probe with an acidic group characteristic to many CYP2C9 substrates. Vivid 2C9 Green also has several aromatic rings capable of pi stacking with key phenylalanine residues in CYP2C9. The other Vivid Probes share physical traits similar to Vivid 2C9 Green. The different probes could lead to different binding interaction and result in altered inhibition profiles for a given compound. Previous studies indicate that CYP2C9 can accommodate multiple substrates simultaneously, which could complicate screening efforts with smaller fluorescent probes. 7, 8 Furthermore, the active site of CYP2C9 may be subject to effects from protein-protein interac-tions with cyt b5 similar to those expressed with CYP3A4. 9 Such protein-protein interactions could potentially interfere with the resultant inhibition profiles and, furthermore, could be dependent on which fluorescent probe was used in screening.
Cytochrome b5 can serve as an auxiliary electron transfer protein in the CYP catalytic cycle. As such, cyt b5 has been cited as a target for protein-protein interactions with CYP enzymes. 10 While the effects that cyt b5 have on CYP metabolism may vary, a clear steric interaction has been cited between cyt b5 and CYP2C9 with respect to the metabolism of S-warfarin. 11 Within this study, CYP2C9 showed increased metabolic capacity toward S-warfarin in the presence of apo and holo cyt b5 and indicates the principal role of b5 is steric. Similar steric interactions between cyt b5 and CYP2C9 could alter the active site pocket where the substrate in question binds or the fluorescent probe binds, thus potentially altering the resultant inhibition profile.
To this end, MFC and the Vivid series of probes were investigated against 19 known CYP2C9 substrates/inhibitors to determine the variance in the corresponding inhibition profiles as a result of using fluorescent probes with different physical characteristics and binding features. In addition, cyt b5 was evaluated for its potential to alter the inhibition profiles of MFC and Vivid 2C9 Green based on the individual interactions with CYP2C9.
MATERIALS AND METHODS

Materials
Enzyme preparations and MFC were purchased from Gentest (Woburn, MA). Vivid 2C9 Green substrate was purchased from Invitrogen (Carlsbad, CA). All other chemicals used were purchased from Sigma-Aldrich (St. Louis, MO) and were of the highest purity available.
Fluorescence assay
Baculosomes containing 12.5 pmol of CYP2C9 + P450 reductase or 10 pmol CYP2C9 + 20 pmol P450 reductase + 10 pmol cyt b5 were incubated with 7 concentrations of MFC and Vivid 2C9 Green. From these studies, the K m and Vmax values were generated to identify the fluorescent probe substrate concentrations to be used for the subsequent studies. For MFC, the K m was 25.2 µM and 29.7 µM with and without cyt b5, respectively. Thus, 30 µM MFC was used for screening incubations with and without cyt b5. Vivid 2C9 Green yielded a K m of 4.8 µM and 1.2 µM with and without cyt b5, respectively. Vivid 2C9 Green was thus screened at 5 µM for those preparations with cyt b5 and 1 µM for preparations without cyt b5. Test compounds were screened at 10 µM, unless otherwise stated, in 0.1 mM potassium phosphate buffer (pH 7.4) in a final volume of 100 µl. The 96-well plate format was preincubated for 3 min at 37°C prior to the addition of NADPH (1 mM final concentration). Total protein content for both enzyme preparations was 0.25 mg/ml. Fluorescence was measured using a Tecan SpectraFluor (Research Triangle Park, NC) plate reader at 1-min intervals for 30 min with excitation = 409 nm, emission = 530 nm for MFC or excitation = 485 nm, emission = 530 nm for Vivid 2C9 Green. Organic solvent amounts were kept constant and did not exceed 1% (v/v). Background fluorescence was measured with all compounds excluding the fluorescent probes to ensure any substrates and/or metabolites generated did not produce background fluorescence at the wavelengths used to measure fluorescent probe turnover.
Mass spectral analysis
HFC metabolite formation was determined with the Sciex API 4000 (PE Sciex, San Francisco, CA) used in negative ion mode with an MRM scan. An Agilent SB-C18 column (2.1 × 50 mm, 3.5 um) was used with a gradient from 0 to 100% B over 4 min (solvent A 0.1% formic acid, solvent B 100% acetonitrile) at a flow rate of 0.4 ml/min to separate analytes. Diclofenac inhibition was carried out using negative ion mode with an MRM scan. The initial concentration of diclofenac was 6 µM, which was determined to be the K m in the recombinant CYP2C9 system. Percentage inhibition was determined by comparison to the control diclofenac-only incubation. The percentage of diclofenac remaining was compared to the incubation with benzbromarone present.
Data analysis
The end point of the reaction was selected at a point at which the production of fluorescence was linear with respect to time (20 min without cyt b5, 30 min for MFC plus cyt b5, and 10 min for Vivid 2C9 Green). Relative fluorescence was calculated by subtracting the fluorescence in each well from the baseline reading at time 0 and was normalized to P450 content and time. Spotfire DecisionSite 7.2 (Somerville, MA) was used to visualize the b 5 results. K m values were derived using a double reciprocal plot, where 1/K m is defined by intersect of the regression line at the x-axis.
RESULTS AND DISCUSSION
Initially, all 19 compounds were screened at a single concentration against each of the fluorescent probes (Fig. 1) . The resultant profiles highlight that compounds inhibited MFC and Vivid 2C9 Blue to a similar extent and that Vivid 2C9 Red and Vivid 2C9 Green are inhibited indistinguishably (Fig. 2) . As a result, the remaining inhibition studies were carried out with MFC and Vivid 2C9 Green. The physical properties, fluorescent parameters, and kinetics for MFC and Vivid 2C9 Green with and without cyt b5 are listed in Table 1 and highlight the different properties of the 2 probes. For example, the molecular weight of MFC is half the molecular weight of Vivid 2C9 Green and has approximately half the nonpolar surface area. The K m for MFC is higher than that of Vivid 2C9 Green with and without cyt b5 present ( Table 1 ). Both probes exhibit increased Vmax when cyt b5 is present, with the effect most pronounced on MFC metabolism. Vivid 2C9 Green showed an alteration of K m in the presence and absence of cyt b5, unlike MFC. The kinetic parameters and response to cyt b5 from MFC and Vivid 2C9 Green were further examined against known CYP2C9 substrates/inhibitors.
The inhibition profiles for the 19 compounds against MFC are plotted in Figure 3A and show a range of activities from potent inhibition (e.g., sulfaphenazole) to strong activation (e.g., benzbromarone). Interestingly, benzbromarone and its analogs are the most potent class of CYP2C9 inhibitors identified to date (data based on S-warfarin inhibition). 12 These data suggest that CYP2C9 may possess characteristics similar to CYP3A4 and that more detailed analysis of the active site may be necessary to fully understand CYP2C9 inhibition. Furthermore, ibuprofen and naproxen showed no inhibition of MFC metabolism. Ibuprofen and naproxen are well-known CYP2C9 substrates. [13] [14] [15] Both naproxen and ibuprofen fit the classic pharmacophore of CYP2C9, possessing an acid group capable of interactions with Arg108 as well as aromatic rings for pi stacking with phenylalanine residues 100, 114, and 476. 14, 16 Ibuprofen metabolism was monitored in conjunction with MFC metabolism, and neither rate deviated compared to samples with only ibuprofen or MFC present individually (data not shown), suggesting that MFC could undergo demethylation in the presence of ibuprofen. Overall, the inhibition profiles of MFC and CYP2C9 illustrate the flexibility of MFC binding and that demethylation of MFC could occur from more than 1 binding orientation in CYP2C9.
Vivid 2C9 Green is a much larger fluorescent probe compared to MFC ( Table 1 ). In addition, Vivid 2C9 Green contains an acid group with several aromatic rings, which is consistent with the pharmacophore features of CYP2C9. The results in Figure 3B show a marked change from MFC. Namely, all compounds were inhibitors of Vivid 2C9 Green metabolism, and 2 novel compounds, DHDB and GW5074, are potent inhibitors of Vivid 2C9 Green metabolism. Overall, the size of Vivid 2C9 Green likely prohibits the binding of additional substrates in the active site when Vivid 2C9 Green is present. The identification of all compounds as inhibitors is optimal for the comparison of inhibition profiles within a chemical series and enables the grouping of compounds based on their inhibition potency. In contrast, MFC data are limited in their ability to group compounds according to their interactions with CYP2C9 because comparisons between activators and inhibitors are not possible at this time. From this perspective, the use of Vivid 2C9 Green may be optimal when screening for drug-drug interactions using fluorescent probe substrates.
Comparison of Fluorescent Probes
The presence of cyt b5 has been shown to alter P450 kinetics. 17 Furthermore, cyt b5 was previously shown to increase Vmax of MFC. 4 However, cyt b5 induced conformational changes to the active site of CYP2C9, and therefore changes in inhibition profiles were not investigated. Such changes have been effectively demonstrated in CYP3A4 with the use of apo cyt b5 and with the pyrrole labeling agent phenyldiazene. 9, 18 Therefore, both fluorescent probes were reevaluated to determine if cyt b5 could produce conformational changes to the P450 binding pocket and manifest in the corresponding inhibition profiles. MFC showed clear differences in the reactions containing cyt b5 from those without b5 (Fig. 4A) . Most striking was DHDB, which was an activator in the absence of cyt b5 but acted as an inhibitor of MFC when cyt b5 was included. Conversely, when cyt b5 was omitted from naproxen and MFC incubations, the metabolism of MFC was inhibited. However, when cyt b5 was present, MFC metabolism was unaffected.
Although some inhibition profiles vary significantly as a result of cyt b5 addition, other interactions were modest in effect. Visualizing the inhibition response of each test compound incubated with cyt b5 and without cyt b5 revealed that compounds with similar structural features produce similar inhibition profiles (Fig.  4A) . For example, sulfone derivatives such as dapsone and 3aminophenyl sulfone were more potent activators of MFC when b 5 was present, whereas lipophilic phenols such as benzbromarone, GW5074, and amiodarone were better activators in the absence of b 5 . In contrast, acid substrates showed no activation but did respond variably to the addition of cyt b5. The variable effects of cyt b5 on the different chemical classes may indicate that each chemical substructure prefers a distinct binding region within the CYP2C9 active site and ultimately control the substrate-binding coordinates. If true, much like CYP3A4, the use of several drugdrug interaction probes may be necessary to determine the true inhibition potential of new chemical entities that interact with CYP2C9 and is currently under investigation.
Compounds activating MFC metabolism were more sensitive to the addition of cyt b5. Metabolic activation has previously been demonstrated for MFC 6 and can be explained by the presence of 2 compounds in the enzyme active site. 19 Therefore, if activation of HFC formation occurs through binding MFC and the test compound simultaneously in the enzyme active site, the presence of cyt b5 could disrupt the spatial arrangement that enables the 2 substrates to bind together in the active site. To confirm that the activation of MFC was not a fluorescent artifact, the HFC metabolite was measured by mass spectrometry and with a fluorescent plate reader. A reasonable correlation was observed, suggesting that the large amount of activation of MFC metabolism is predominantly a result of increased HFC formation and not an artifact (Fig. 5) . The size of Vivid 2C9 Green likely prohibits the binding of multiple compounds together in the active site because the enzyme is sufficiently filled with the larger fluorescent substrate.
In conclusion, the use of MFC and Vivid 2C9 Green demonstrate that the identification of CYP2C9 inhibitors is probe substrate dependent. The primary difference between MFC and Vivid 2C9 Green appears to be the activation of MFC metabolism in the presence of several compounds. The increased fluorescent signal was linked to HFC formation as determined by mass spectrometry. In contrast to the activation of MFC, Vivid 2C9 Green produces inhibition and enables the direct comparison to be made only be- 
